Taiwan Bio and TRACT Therapeutics, Inc. Announce Strategic Partnership to Advance a Novel Therapeutic Approach for Preventing Rejection in Solid Organ Transplant
Retrieved on:
Mittwoch, Dezember 6, 2023
Research, Surgery, Hospitals, Genetics, Clinical Trials, Biotechnology, Pharmaceutical, Health, Science, Other Science, Harold Fowler McCormick, GMP, Hope, Therapy, Northwestern University, CDMO, Transplant, Patient, Multimedia, FDA, Autoimmune disease, Cell engineering, Medical College of Wisconsin, Organ transplantation, MD, CGMP, Partnership, Doctor of Philosophy, Medical college, Phase II, Quality of life, Pharmaceutical industry
Taiwan Bio and TRACT Therapeutics are pleased to announce a new strategic partnership to advance a cellular therapy to revolutionize the prevention of allograft rejection in solid organ transplant.
Key Points:
- Taiwan Bio and TRACT Therapeutics are pleased to announce a new strategic partnership to advance a cellular therapy to revolutionize the prevention of allograft rejection in solid organ transplant.
- View the full release here: https://www.businesswire.com/news/home/20231206255985/en/
This partnership leverages Taiwan Bio’s world-class expertise in cellular therapy manufacturing and TRACT Therapeutics’ innovative immune modulating regulatory T cell therapy platform. - "We believe that this collaboration holds tremendous promise for patients seeking better therapeutic options," said Cyrus Yang, COO of Taiwan Bio.
- Our Phase 2 trial represents a significant step forward in our mission to provide solid organ transplant patients with better treatment options."